학술논문
Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial
Document Type
Article
Author
Rawstron, Andy; Webster, Nichola; Dalal, Surita; de Tute, Ruth M; Bell, Sue; Cairns, David Allan; Girvan, Sean; Greatorex, Natasha; Hockaday, Anna; Jackson, Sharon; Phillips, David; Stones, David; Allsup, David; Bloor, Adrian John Clifton; Sarma, Anita; Varghese, Abraham Mullasseril; Munir, Talha; Hillmen, Peter
Source
Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p632-632, 1p
Subject
Language
ISSN
00064971; 15280020
Abstract
Time-limited treatments for CLL are under investigation but the optimal target for treatment cessation is not fully clear. Bone marrow (BM) measurable residual disease (MRD) is usually the most sensitive measure but would be too invasive to guide treatment in a routine setting. The iwCLL threshold of BM uMRD4 (<0.01%) has been demonstrated to be a powerful indicator of improved outcomes across multiple different trials and the aim of this analysis is to determine the feasibility of using PB MRD analysis to identify patients who have attained BM uMRD4.